This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (3176)  • Contact me when this article is cited  Related Content  • Related letters  • Related article  • Similar articles in JAMA  Topic Collections  • Women's Health  • Menopause  • Alert me on articles by topic  Social Bookmarking   What's this?

Stephen Hulley, MD; Deborah Grady, MD; Trudy Bush, PhD; Curt Furberg, MD, PhD; David Herrington, MD; Betty Riggs, MD; Eric Vittinghoff, PhD; for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group

JAMA. 1998;280:605-613.

Context.— Observational studies have found lower rates of coronary heart disease (CHD) in postmenopausal women who take estrogen than in women who do not, but this potential benefit has not been confirmed in clinical trials.

Objective.— To determine if estrogen plus progestin therapy alters the risk for CHD events in postmenopausal women with established coronary disease.

Design.— Randomized, blinded, placebo-controlled secondary prevention trial.

Setting.— Outpatient and community settings at 20 US clinical centers.

Participants.— A total of 2763 women with coronary disease, younger than 80 years, and postmenopausal with an intact uterus. Mean age was 66.7 years.

Intervention.— Either 0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate in 1 tablet daily (n=1380) or a placebo of identical appearance (n=1383). Follow-up averaged 4.1 years; 82% of those assigned to hormone treatment were taking it at the end of 1 year, and 75% at the end of 3 years.

Main Outcome Measures.— The primary outcome was the occurrence of nonfatal myocardial infarction (MI) or CHD death. Secondary cardiovascular outcomes included coronary revascularization, unstable angina, congestive heart failure, resuscitated cardiac arrest, stroke or transient ischemic attack, and peripheral arterial disease. All-cause mortality was also considered.

Results.— Overall, there were no significant differences between groups in the primary outcome or in any of the secondary cardiovascular outcomes: 172 women in the hormone group and 176 women in the placebo group had MI or CHD death (relative hazard [RH], 0.99; 95% confidence interval [CI], 0.80-1.22). The lack of an overall effect occurred despite a net 11% lower low-density lipoprotein cholesterol level and 10% higher high-density lipoprotein cholesterol level in the hormone group compared with the placebo group (each P<.001). Within the overall null effect, there was a statistically significant time trend, with more CHD events in the hormone group than in the placebo group in year 1 and fewer in years 4 and 5. More women in the hormone group than in the placebo group experienced venous thromboembolic events (34 vs 12; RH, 2.89; 95% CI, 1.50-5.58) and gallbladder disease (84 vs 62; RH, 1.38; 95% CI, 1.00-1.92). There were no significant differences in several other end points for which power was limited, including fracture, cancer, and total mortality (131 vs 123 deaths; RH, 1.08; 95% CI, 0.84-1.38).

Conclusions.— During an average follow-up of 4.1 years, treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of CHD events in postmenopausal women with established coronary disease. The treatment did increase the rate of thromboembolic events and gallbladder disease. Based on the finding of no overall cardiovascular benefit and a pattern of early increase in risk of CHD events, we do not recommend starting this treatment for the purpose of secondary prevention of CHD. However, given the favorable pattern of CHD events after several years of therapy, it could be appropriate for women already receiving this treatment to continue.

From the University of California, San Francisco (Drs Hulley, Grady, and Vittinghoff); The Johns Hopkins University, Baltimore, Md (Dr Bush); Wake Forest University School of Medicine, Winston-Salem, NC (Drs Furberg and Herrington); and Wyeth-Ayerst Research, Radnor, Pa (Dr Riggs).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED LETTERS

Hormone Replacement Therapy for Secondary Prevention of Coronary Heart Disease
Cynthia X. Pan, Jeremy Boal, for the Geriatrics Journal Club, Emily Banks, Valerie Beral, Paul J. L. Ong, Morten B. Sorensen, Christopher S. Hayward, Carolyn M. Webb, Peter Collins, Jerome L. Sullivan, Susan R. Heckbert, Noel S. Weiss, Bruce M. Psaty, Jan P. Vandenbroucke, Stephen Hulley, Deborah Grady, Eric Vittinghoff, Trudy Bush, Curt Furberg, David Herrington, Betty Riggs, and Diana B. Petitti
JAMA. 1999;281(9):794-797.
EXTRACT | FULL TEXT  

Early Risks of Hormone Therapy in Patients With Coronary Heart Disease
Nanette K. Wenger, Genell L. Knatterud, and Paul L. Canner
JAMA. 2000;284(1):41-43.
EXTRACT | FULL TEXT  

What Is the Best Evidence for Making Clinical Decisions?
Nirav R. Shah, Gordon H. Guyatt, David Naylor, W. Scott Richardson, Lee Green, R. Brian Haynes, Mark C. Wilson, Deborah J. Cook, and Roman Z. Jaeschke
JAMA. 2000;284(24):3127-3128.
EXTRACT | FULL TEXT  

Postmenopausal Hormone Replacement, Body Mass Index, and Quality of Life
Carmen Rodriguez, Eugenia E. Calle, Mark A. Hlatky, and Derek Boothroyd
JAMA. 2002;287(17):2210-2211.
EXTRACT | FULL TEXT  

Risks of Postmenopausal Hormone Replacement
Nina Radford, Tim Church, Frank E. Speizer, Beverley E. Pearson Murphy, Susan R. Davis, Henry G. Burger, William H. Goodson III, Henk R. Franke, Ishay Lev, Amnon Lahad, Aharon Karni, Eric Brunner, Raanan Gillon, Houston H. Stokes, Edeltraut Garbe, Samy Suissa, Sean I. Savitz, and Lou Caplan
JAMA. 2002;288(22):2819-2824.
EXTRACT | FULL TEXT  

Risk of Hemolytic Uremic Syndrome From Antibiotic Treatment of Escherichia coli O157:H7 Colitis
Christopher J. Gill, Davidson H. Hamer, Joseph Lau, Craig S. Wong, John R. Brandt, Phillip I. Tarr, Sandra L. Watkins, Marguerite A. Neill, Dennis G. Maki, and Nasia Safdar
JAMA. 2002;288(24):3110-3112.
EXTRACT | FULL TEXT  

Estrogen Replacement and Risk of Alzheimer Disease
Amnon Lahad and Lev Ishay
JAMA. 2003;289(9):1100-1101.
EXTRACT | FULL TEXT  

Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial
The Women's Health Initiative Steering Committee
JAMA. 2004;291(14):1701-1712.
ABSTRACT | FULL TEXT  

RELATED ARTICLE

Hormone Replacement Therapy and Heart Disease Prevention: Experimentation Trumps Observation
Diana B. Petitti
JAMA. 1998;280(7):650-652.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Postmenopausal Hypertension: Mechanisms and Therapy
Barton and Meyer
Hypertension 2009;54:11-18.
FULL TEXT  

Postmenopausal Hormone Treatment
Hulley and Grady
JAMA 2009;301:2493-2495.
FULL TEXT  

Growth hormone, menopause and ageing: no definite evidence for 'rejuvenation' with growth hormone
Fanciulli et al.
Hum Reprod Update 2009;15:341-358.
ABSTRACT | FULL TEXT  

Prevention of atrial fibrillation: another good reason to recommend statins to women?
Ashikaga and Marine
Heart 2009;95:693-694.
FULL TEXT  

Baroreflex sensitivity varies during the rat estrous cycle: role of gonadal steroids
Goldman et al.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009;296:R1419-R1426.
ABSTRACT | FULL TEXT  

Principles of Designing a Cohort Study in Orthopaedics
Bryant et al.
JBJS 2009;91:10-14.
ABSTRACT | FULL TEXT  

Hormone replacement therapy in women with systemic lupus erythematosus and risk of cardiovascular disease
Hochman et al.
Lupus 2009;18:313-317.
ABSTRACT  

Interference of Progestins With Endothelial Actions of Estrogens: A Matter of Glucocorticoid Action or Deprivation?
Arnal et al.
Arterioscler. Thromb. Vasc. Bio. 2009;29:441-443.
FULL TEXT  

Low-Density Lipoprotein Cholesterol Reduction and Prevention of Cardiovascular Disease
Stein
Mayo Clin Proc. 2009;84:307-309.
FULL TEXT  

Landmarks in the History of Cancer Epidemiology
Greenwald and Dunn
Cancer Res. 2009;69:2151-2162.
ABSTRACT | FULL TEXT  

Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK
Lekander et al.
Menopause Int 2009;15:19-25.
ABSTRACT | FULL TEXT  

Aspirin Therapy in Women: Back to the ABCs
Mora
Circ Cardiovasc Qual Outcomes 2009;2:63-64.
FULL TEXT  

Effects of aglycone genistein in a rat experimental model of postmenopausal metabolic syndrome
Bitto et al.
J Endocrinol 2009;200:367-376.
ABSTRACT | FULL TEXT  

Effects of the Selective Estrogen Receptor Modulator Raloxifene on Coronary Outcomes in The Raloxifene Use for the Heart Trial: Results of Subgroup Analyses by Age and Other Factors
Collins et al.
Circulation 2009;119:922-930.
ABSTRACT | FULL TEXT  

HDL cholesterol and cardiovascular risk
Ghali and Rodondi
BMJ 2009;338:a3065-a3065.
FULL TEXT  

Overview of clinical research design
Hartung and Touchette
Am J Health Syst Pharm 2009;66:398-408.
ABSTRACT | FULL TEXT  

Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women
Chlebowski et al.
NEJM 2009;360:573-587.
ABSTRACT | FULL TEXT  

Rapid Estrogen Receptor-{alpha} Activation Improves Ischemic Tolerance in Aged Female Rats through a Novel Protein Kinase C{epsilon}-Dependent Mechanism
Novotny et al.
Endocrinology 2009;150:889-896.
ABSTRACT | FULL TEXT  

Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women
Rebbeck et al.
Carcinogenesis 2009;30:269-274.
ABSTRACT | FULL TEXT  

Reassessing Benefits and Risks of Hormone Therapy
Gass et al.
AMERICAN JOURNAL OF LIFESTYLE MEDICINE 2009;3:29-43.
ABSTRACT  

Estradiol increases angiotensin II type 1 receptor in hearts of ovariectomized rats
Ricchiuti et al.
J Endocrinol 2009;200:75-84.
ABSTRACT | FULL TEXT  

Validity and reliability of measurement instruments used in research
Kimberlin and Winterstein
Am J Health Syst Pharm 2008;65:2276-2284.
ABSTRACT | FULL TEXT  

Approach to the Patient with Menopausal Symptoms
Martin and Manson
J. Clin. Endocrinol. Metab. 2008;93:4567-4575.
ABSTRACT | FULL TEXT  

Inflammatory, Lipid, Thrombotic, and Genetic Markers of Coronary Heart Disease Risk in the Women's Health Initiative Trials of Hormone Therapy
Rossouw et al.
Arch Intern Med 2008;168:2245-2253.
ABSTRACT | FULL TEXT  

Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen
Davis et al.
NEJM 2008;359:2005-2017.
ABSTRACT | FULL TEXT  

Evaluating the Evidence: Is There a Rigid Hierarchy?
Ho et al.
Circulation 2008;118:1675-1684.
FULL TEXT  

Participant Perspectives on a Yoga Intervention for Menopausal Symptoms
Taylor et al.
Complementary Health Practice Review 2008;13:171-181.
ABSTRACT  

Review: Prevention of coronary heart disease in women
Rohit Seth Loomba and Arora
Ther Adv Cardiovasc Dis 2008;2:321-327.
ABSTRACT  

Long term androgen deprivation therapy in prostate cancer
Ockrim and Abel
BMJ 2008;337:a1361-a1361.
FULL TEXT  

Pharmacologic Treatment of Low Bone Density or Osteoporosis to Prevent Fractures: A Clinical Practice Guideline from the American College of Physicians
Qaseem et al.
ANN INTERN MED 2008;149:404-415.
ABSTRACT | FULL TEXT  

A Lifestyle Approach for Primary Cardiovascular Disease Prevention in Perimenopausal to Early Postmenopausal Women
Pettee et al.
AMERICAN JOURNAL OF LIFESTYLE MEDICINE 2008;2:421-431.
ABSTRACT  

Is LDL-C Passed Its Prime?: The Emerging Role of Non-HDL, LDL-P, and ApoB in CHD Risk Assessment
Davidson
Arterioscler. Thromb. Vasc. Bio. 2008;28:1582-1583.
FULL TEXT  

Lipoprotein Particle Concentrations May Explain the Absence of Coronary Protection in the Women's Health Initiative Hormone Trials
Hsia et al.
Arterioscler. Thromb. Vasc. Bio. 2008;28:1666-1671.
ABSTRACT | FULL TEXT  

Epidemiology of Cytokines: The Women On the Move through Activity and Nutrition (WOMAN) Study
Wong et al.
Am J Epidemiol 2008;168:443-453.
ABSTRACT | FULL TEXT  

Effects of long-term treatment with 8-prenylnaringenin and oral estradiol on the GH-IGF-1 axis and lipid metabolism in rats
Bottner et al.
J Endocrinol 2008;198:395-401.
ABSTRACT | FULL TEXT  

Dose-dependent cardiac effect of oestrogen replacement in mice post-myocardial infarction
Zhan et al.
Exp Physiol 2008;93:982-993.
ABSTRACT | FULL TEXT  

Influence of Aging and Menopause on Lipids and Lipoproteins in Women
Kolovou and Bilianou
ANGIOLOGY 2008;59:54S-57S.
ABSTRACT  

Oestrogen plays a permissive role in cardioprotection
Cohen and Downey
Cardiovasc Res 2008;79:353-354.
FULL TEXT  

Lipoprotein(a), Hormone Replacement Therapy, and Risk of Future Cardiovascular Events
Suk Danik et al.
J Am Coll Cardiol 2008;52:124-131.
ABSTRACT | FULL TEXT  

Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications
DAVIDSON
Cleveland Clinic Journal of Medicine 2008;75:479-496.
FULL TEXT  

Invited Commentary: Postmenopausal Unopposed Estrogen and Breast Cancer Risk in the Women's Health Initiative--Before and Beyond
Linet
Am J Epidemiol 2008;167:1416-1420.
ABSTRACT | FULL TEXT  

Sexual Dimorphism of the Aging Kidney: Role of Nitric Oxide Deficiency
Baylis
Physiology 2008;23:142-150.
ABSTRACT | FULL TEXT  

Osteoporosis: Management and Treatment Strategies for Orthopaedic Surgeons
Gehrig et al.
JBJS 2008;90:1362-1374.
FULL TEXT  

Effect of Low-Dose Oral Contraceptives on Metabolic Risk Factors in African-American Women
Frempong et al.
J. Clin. Endocrinol. Metab. 2008;93:2097-2103.
ABSTRACT | FULL TEXT  

Vascular Actions of Estrogens: Functional Implications
Miller and Duckles
Pharmacol. Rev. 2008;60:210-241.
ABSTRACT | FULL TEXT  

Estrogen potentiates constrictor prostanoid function in female rat aorta by upregulation of cyclooxygenase-2 and thromboxane pathway expression
Li et al.
Am. J. Physiol. Heart Circ. Physiol. 2008;294:H2444-H2455.
ABSTRACT | FULL TEXT  

Kidney Dysfunction and Sudden Cardiac Death Among Women With Coronary Heart Disease
Deo et al.
Hypertension 2008;51:1578-1582.
ABSTRACT | FULL TEXT  

Menopausal Complaints Are Associated With Cardiovascular Risk Factors
Gast et al.
Hypertension 2008;51:1492-1498.
ABSTRACT | FULL TEXT  

A Comparison of the Short-Term Effects of Oral Conjugated Equine Estrogens Versus Transdermal Estradiol on C-Reactive Protein, Other Serum Markers of Inflammation, and Other Hepatic Proteins in Naturally Menopausal Women
Shifren et al.
J. Clin. Endocrinol. Metab. 2008;93:1702-1710.
ABSTRACT | FULL TEXT  

Intracoronary Genistein Acutely Increases Coronary Blood Flow in Anesthetized Pigs through {beta}-Adrenergic Mediated Nitric Oxide Release and Estrogenic Receptors
Grossini et al.
Endocrinology 2008;149:2678-2687.
ABSTRACT | FULL TEXT  

Estrogen, nitric oxide, and hypertension differentially modulate agonist-induced contractile responses in female transgenic (mRen2)27 hypertensive rats
Brosnihan et al.
Am. J. Physiol. Heart Circ. Physiol. 2008;294:H1995-H2001.
ABSTRACT | FULL TEXT  

Persistent Hot Flushes in Older Postmenopausal Women
Huang et al.
Arch Intern Med 2008;168:840-846.
ABSTRACT | FULL TEXT  

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt et al.
BMJ 2008;336:924-926.
FULL TEXT  

Progestogens regulate endothelial actin cytoskeleton and cell movement via the actin-binding protein moesin
Fu et al.
Mol Hum Reprod 2008;14:225-234.
ABSTRACT | FULL TEXT  

17{beta}-Estradiol Increases Basal but Not Bradykinin-Stimulated Release of Active t-PA in Young Postmenopausal Women
Pretorius et al.
Hypertension 2008;51:1190-1196.
ABSTRACT | FULL TEXT  

Medroxyprogesterone Abrogates the Inhibitory Effects of Estradiol on Vascular Smooth Muscle Cells by Preventing Estradiol Metabolism
Dubey et al.
Hypertension 2008;51:1197-1202.
ABSTRACT | FULL TEXT  

Psychological and Clinical Factors Implicated in Decision Making About a Trial of Low-Dose Tamoxifen in Hormone Replacement Therapy Users
Rondanina et al.
JCO 2008;26:1537-1543.
ABSTRACT | FULL TEXT  

Physiological Concentration of 17{beta}-Estradiol on Sympathetic Reinnervation in Ovariectomized Infarcted Rats
Lee et al.
Endocrinology 2008;149:1205-1213.
ABSTRACT | FULL TEXT  

Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis
MacLean et al.
ANN INTERN MED 2008;148:197-213.
ABSTRACT | FULL TEXT  

Evidence-based common sense?
Sherman
cfp 2008;54:166-168.
FULL TEXT  

Bon sens fonde sur des donnees probantes?
Sherman
cfp 2008;54:169-171.
FULL TEXT  

Time Since Menopause Influences the Acute and Chronic Effect of Estrogens on Endothelial Function
Vitale et al.
Arterioscler. Thromb. Vasc. Bio. 2008;28:348-352.
ABSTRACT | FULL TEXT  

Effect of ovariectomy on cardiac gene expression: inflammation and changes in SOCS gene expression
Hamilton et al.
Physiol. Genomics 2008;32:254-263.
ABSTRACT | FULL TEXT  

Shedding light on high-density lipoprotein cholesterol: the post-ILLUMINATE era.
Lavie and Milani
J Am Coll Cardiol 2008;51:56-58.
FULL TEXT  

Can Women Be Identified That Will Derive Considerable Cardiovascular Benefits from Postmenopausal Estrogen Therapy?
Clarkson
J. Clin. Endocrinol. Metab. 2008;93:37-39.
FULL TEXT  

Progressive Diastolic Dysfunction in the Female mRen(2).Lewis Rat: Influence of Salt and Ovarian Hormones
Groban et al.
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2008;63:3-11.
ABSTRACT | FULL TEXT  

A well-conducted randomized trial that establishes no benefit of therapy is an important medical advance
Garg et al.
Nephrol Dial Transplant 2008;23:52-55.
FULL TEXT  

Cardioprotection in female rats subjected to chronic volume overload: synergistic interaction of estrogen and phytoestrogens
Gardner et al.
Am. J. Physiol. Heart Circ. Physiol. 2008;294:H198-H204.
ABSTRACT | FULL TEXT  

Differential Dietary Nutrient Intake according to Hormone Replacement Therapy Use: An Underestimated Confounding Factor in Epidemiologic Studies?
Vercambre et al.
Am J Epidemiol 2007;166:1451-1460.
ABSTRACT | FULL TEXT  

Pharmacogenetic Modulation of Combined Hormone Replacement Therapy by Progesterone-Metabolism Genotypes in Postmenopausal Breast Cancer Risk
Rebbeck et al.
Am J Epidemiol 2007;166:1392-1399.
ABSTRACT | FULL TEXT  

Endogenous Testosterone and Mortality Due to All Causes, Cardiovascular Disease, and Cancer in Men: European Prospective Investigation Into Cancer in Norfolk (EPIC-Norfolk) Prospective Population Study
Khaw et al.
Circulation 2007;116:2694-2701.
ABSTRACT | FULL TEXT  

New findings from non-linear longitudinal modelling of menopausal hormone changes
Dennerstein et al.
Hum Reprod Update 2007;13:551-557.
ABSTRACT | FULL TEXT  

Cannabis use and psychosis: the origins and implications of an association
Macleod
Adv. Psychiatr. Treat. 2007;13:400-411.
ABSTRACT | FULL TEXT  

Regulation of Alternative Splicing of Liver Scavenger Receptor Class B Gene by Estrogen and the Involved Regulatory Splicing Factors
Zhang et al.
Endocrinology 2007;148:5295-5304.
ABSTRACT | FULL TEXT  

Sex influences the susceptibility to reperfusion-induced sustained ventricular tachycardia and beta-adrenergic receptor blockade in conscious rats
Lujan et al.
Am. J. Physiol. Heart Circ. Physiol. 2007;293:H2799-H2808.
ABSTRACT | FULL TEXT  

Can Computerized Decision Support Help Patients Make Complex Treatment Decisions? A Randomized Controlled Trial of an Individualized Menopause Decision Aid
Col et al.
Med Decis Making 2007;27:585-598.
ABSTRACT  

Transforming Growth Factor Activity Is a Key Determinant for the Effect of Estradiol on Fatty Streak Deposit in Hypercholesterolemic Mice
Gourdy et al.
Arterioscler. Thromb. Vasc. Bio. 2007;27:2214-2221.
ABSTRACT | FULL TEXT  

Estrogen Protects Against Increased Blood Pressure in Postpubertal Female Growth Restricted Offspring
Ojeda et al.
Hypertension 2007;50:679-685.
ABSTRACT | FULL TEXT  

Low Serum Testosterone and High Serum Estradiol Associate With Lower Extremity Peripheral Arterial Disease in Elderly Men: The MrOS Study in Sweden
Tivesten et al.
J Am Coll Cardiol 2007;50:1070-1076.
ABSTRACT | FULL TEXT  

2-Methoxyestradiol: A Potential Treatment for Multiple Proliferative Disorders
Dubey et al.
Endocrinology 2007;148:4125-4127.
FULL TEXT  

The Endogenous Estradiol Metabolite 2-Methoxyestradiol Reduces Atherosclerotic Lesion Formation in Female Apolipoprotein E-Deficient Mice
Bourghardt et al.
Endocrinology 2007;148:4128-4132.
ABSTRACT | FULL TEXT  

Invited Commentary: Hormone Therapy and Risk of Coronary Heart Disease Why Renew the Focus on the Early Years of Menopause?
Manson and Bassuk
Am J Epidemiol 2007;166:511-517.
ABSTRACT | FULL TEXT  

Hormones and Heart Disease in Women: The Timing Hypothesis
Barrett-Connor
Am J Epidemiol 2007;166:506-510.
ABSTRACT | FULL TEXT  

Medroxyprogesterone acetate prevents the cardioprotective and anti-inflammatory effects of 17beta-estradiol in an in vivo model of myocardial ischemia and reperfusion
Booth and Lucchesi
Am. J. Physiol. Heart Circ. Physiol. 2007;293:H1408-H1415.
ABSTRACT | FULL TEXT  

ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
Anderson et al.
J Am Coll Cardiol 2007;50:e1-e157.
FULL TEXT  

Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women
Vickers et al.
BMJ 2007;335:239-239.
ABSTRACT | FULL TEXT  

Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists
Collins et al.
Eur Heart J 2007;28:2028-2040.
ABSTRACT | FULL TEXT